RightFit
Not yet recruitingPhase 1

Senolytics for Secondary Progressive MS

Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
50 Years to 85 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 3 months, 1 year

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months."
  • "Participants will also be followed for one year from enrollment to monitor for treatment effects."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: 1. Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria 2. Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone. 3. Evidence of MS progression over the past 12 months. Exclusion Criteria: 1. Unstable coronary artery disease (myocardial infarction within 6 months or angina) 2. Hospitalization within 6 months 3. Stroke or transient ischemic attack in the past 6 months 4. Pulmonary arterial hypertension 5. Current or chronic history of liver disease 6. Alzheimer's or Parkinson's disease 7. Drug or alcohol abuse in the previous 5 years 8. History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage 9. History of angina or myocardial infarction, arrhythmia, or heart failure at any time 10. QTc prolongation 11. Anemia (Hgb\<9), thrombocytopenia (platelets\<50,000 per microliter), or neutropenia (ANC\< 1000 per microliter) 12. Moderate hypokalemia (2.9 mmol/L) and moderate hypomagnesemia (0.9-1.1 mg/dL or 0.37-0.45 mmol/L) 13. ALT/AST \>1.5x ULN, total bilirubin \>ULN, and alkaline phosphatase \>2x ULN 14. Chronic renal disease (glomerular filtration rate \< 30 mL/min/1.73 m2) 15. Alcohol intake greater than 2 drinks/day for men and greater than 1 drink/day for women 16. Anti-arrhythmic medications known to cause QTc prolongation 17. Antipsychotics and anxiolytics 18. Anti-platelet or anti-coagulant medications other than aspirin 19. Quinolone antibiotics 20. Pregnant or lactating subjects or subjects intending to become pregnant or to donate egg/sperm 21. Participants with p16INK4a below the median of SPMS patients in the OSU Aging and MS Cohort 22. Use of drugs metabolized by the same liver enzymes as D or Q

Study sites (1)

OH